GlassScriptPhysician profile
Scott Massey
NPI 1407293772
$2,982.72
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $413 · 2021: $693 · 2022: $726 · 2023: $394 · 2024: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $922.45 | 2021-2024 | |
| Abbott Laboratories | $586.41 | 2021-2024 | Proclaim |
| Amgen INC. | $172.97 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $162.84 | 2020-2022 | |
| Lilly USA, LLC | $162.66 | 2019-2022 | |
| Foundation Fusion Solutions, LLC | $143.74 | 2021-2022 | |
| Flowonix Medical Incorporated | $117.26 | 2019-2020 | |
| Electronic Waveform Lab, INC. | $103.81 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $74.05 | 2019-2021 | |
| Alkermes, INC. | $57.53 | 2019-2022 | |
| Tersera Therapeutics LLC | $56.34 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.71 | 2022-2024 | Relistor, Trulance, Xifaxan |
| Biodelivery Sciences International, INC. | $44.63 | 2020-2021 | |
| Novo Nordisk INC | $36.50 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.34 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $29.50 | 2021 | |
| Si-Bone, INC. | $28.81 | 2023 | |
| Medtronic USA, INC. | $23.52 | 2020 | |
| Boston Scientific Corporation | $20.98 | 2019 | |
| Fidia Pharma USA INC. | $20.62 | 2023 | Hymovis |
| Biohaven Pharmaceutical Holding Company LTD. | $18.95 | 2022 | |
| Gilead Sciences, INC. | $17.88 | 2020 | |
| Amarin Pharma, INC. | $16.33 | 2020 | |
| Indivior INC. | $16.06 | 2019 | |
| Allergan, INC. | $14.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.45 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.42 | 2023 | Farxiga |
| Horizon Therapeutics Plc | $12.45 | 2020 | |
| Bioventus LLC | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Massey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.